The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer
Open accessAbstract
BACKGROUND: Advances in the treatment of metastatic colorectal cancer (mCRC) in the last decade have significantly improved survival; however, simple biomarkers to predict response or toxicity have not been identified, which are applicable to all community oncology settings worldwide. The use of inflammatory markers based on differential white-cell counts, such as the neutrophil/lymphocyte ratio (NLR), may be simple and readily available biomarkers. METHODS: Clinical information and baseline laboratory parameters were available for 349 patients, from two independent cohorts, with unresectable mCRC receiving first-line palliative chemotherapy. Associations between baseline prognostic variables, including inflammatory markers such as the NLR and tumour response, progression and survival were investigated. RESULTS: In the training cohort, combination-agent chemotherapy (P=0.001) and NLR ≤ 5 (P=0.003) were associated with improved clinical benefit. The ECOG performance status 1 (P=0.002), NLR>5 (P=0.01), hypoalbuminaemia (P=0.03) and single-agent chemotherapy (P<0.0001) were associated with increased risk of progression. The ECOG performance status ≥ 1 (P=0.004) and NLR>5 (P=0.002) predicted worse overall survival (OS). The NLR was confirmed to independently predict OS in the validation cohort (P<0.0001). Normalisation of the NLR after one cycle of chemotherapy in a subset of patients resulted in improved progression-free survival (P=0.012). CONCLUSION: These results have highlighted NLR as a potentially useful clinical biomarker of systemic inflammatory response in predicting clinically meaningful outcomes in two independent cohorts. Results of this study have also confirmed the importance of a chronic systemic inflammatory response influencing clinical outcomes in patients with mCRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Higgins, S. M. F., Macken, A. P., Cullen, W., Saunders, J., Dunne, C. P., & O’Gorman, C. S. (2013) · PubMed · doi:10.34961/9953 · Cited by 4,805
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
Self-citationEffector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · cited 1×
“Lymphocytic infiltration in primary colorectal tumour tissue with different lymphocyte subpopulations has been investigated as potential prognostic factors (Pagès et al, 2005; Galon et al, 2006).”
BackgroundBokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,636
Mathers, C. (2008) · International Encyclopedia of Public Health · doi:10.1016/b978-012373960-5.00335-x · Cited by 1,121
Systemic inflammation, nutritional status and survival in patients with cancer
McMillan, D. C. (2009) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32832a7902 · Cited by 1,001
Roxburgh, C. S., & McMillan, D. C. (2010) · Future Oncology · doi:10.2217/fon.09.136 · Cited by 998
Cited by
DNA methylation arrays as surrogate measures of cell mixture distribution
Houseman, E. A., Accomando, W. P., Koestler, D. C., Christensen, B. C., Marsit, C. J., Nelson, H. H., Wiencke, J. K., & Kelsey, K. T. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-86 · Cited by 3,175
Templeton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F. E., Aneja, P., Ocaña, A., Leibowitz-Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 2,829
Cancer-related inflammation and treatment effectiveness
Diakos, C. I., Charles, K. A., McMillan, D. C., & Clarke, S. J. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70263-3 · Cited by 2,193
Self-citationThe systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
Guthrie, G. J. K., Charles, K. A., Roxburgh, C. S. D., Horgan, P. G., McMillan, D. C., & Clarke, S. J. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.03.010 · Cited by 1,552
Self-citationNeutrophil diversity and plasticity in tumour progression and therapy
Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R., & Mantovani, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0281-y · Cited by 1,285
Templeton, A. J., Ace, O., McNamara, M. G., Al-Mubarak, M., Vera-Badillo, F. E., Hermanns, T., Šeruga, B., Ocaña, A., Tannock, I. F., & Amir, E. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0146 · Cited by 719
A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer
Proctor, M. J., McMillan, D. C., Morrison, D. S., Fletcher, C. D., Horgan, P. G., & Clarke, S. J. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.292 · Cited by 508
Self-citationLi, M.-X., Liu, X.-M., Zhang, X.-F., Zhang, J.-F., Wang, W.-L., Zhu, Y., Dong, J., Cheng, J.-W., Liu, Z.-W., Ma, L., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28536 · Cited by 459
Sun, K., Chen, S., Xu, J., Li, G., & He, Y. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1714-3 · Cited by 439
The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment
Sionov, R. V., Fridlender, Z. G., & Granot, Z. (2015) · Cancer Microenvironment · doi:10.1007/s12307-014-0147-5 · Cited by 416
Jafri, S. H., Shi, R., & Mills, G. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-158 · Cited by 389
Rao, H.-L., Chen, J.-W., Li, M., Xiao, Y.-B., Fu, J., Zeng, Y.-X., Cai, M.-Y., & Xie, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030806 · Cited by 327
Mei, Z., Shi, L., Wang, B., Yang, J., Xiao, Z., Du, P., Wang, Q., & Yang, W. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.005 · Cited by 304
Immunomonitoring and prognostic relevance of neutrophils in clinical trials
Donskov, F. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.02.001 · Cited by 293
Lee, S., Oh, S. Y., Kim, S. H., Lee, J. H., Kim, M. C., Kim, K. H., & Kim, H.-J. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-350 · Cited by 281
Neutrophils: important contributors to tumor progression and metastasis
Swierczak, A., Mouchemore, K. A., Hamilton, J. A., & Anderson, R. L. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9594-9 · Cited by 220
Kiely, B. E., Martin, A. J., Tattersall, M. H. N., Nowak, A. K., Goldstein, D., Wilcken, N. R. C., Wyld, D. K., Abdi, E. A., Glasgow, A., Beale, P. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.7821 · Cited by 62
Metadata
- Authors
- Chua, W., Charles, K. A., Baracos, V. E., & Clarke, S. J.
- Venue
- British Journal of Cancer
- Published
- 2011-03-29
- Volume
- 104
- Issue
- 8
- Pages
- 1288-1295
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2020684281
- Cited by
- 468
- References
- 34
- FWCI
- 15.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.